Aaron Koenig, MD
Dr. Koenig currently serves as Chief Medical Officer for Delix Therapeutics. Dr. Koenig received his MD from the University of Pennsylvania and completed a residency in Adult Psychiatry at Western Psychiatric Institute & Clinic of UPMC, where he also served as a Chief Resident for Research. Dr. Koenig then completed a clinical fellowship in Geriatric Psychiatry at the Hospital of the University of Pennsylvania, followed by a post-doctoral research fellowship in Psychiatric Genetics and Translational Research at the Harvard T.H. Chan School of Public Health. He subsequently received a faculty appointment at Harvard Medical School, where he served as a clinical investigator at the Massachusetts Alzheimer’s Disease Research Center and practiced as a clinician in the Memory Disorders Unit in the Department of Neurology at Massachusetts General Hospital.
Prior to joining Delix, Dr. Koenig was Vice President of Early Medical Science (Clinical Development) at Sage Therapeutics. During his time at Sage, Dr. Koenig was responsible for conceptualizing, designing, and executing on Sage’s clinical-stage neuropsychiatry programs, from first-in-human to pivotal Ph2b studies. In this capacity, Dr. Koenig oversaw assets within Sage’s early and mid-stage neuropsychiatry portfolio and managed a team of physicians and clinical scientists to ensure seamless execution of high-priority clinical development programs. Prior to Sage, Dr. Koenig served as an Associate Medical Director in the Alzheimer’s Disease Research Unit at Biogen.
Dr. Koenig is a diplomate of the American Board of Psychiatry and Neurology (ABPN) and retains active board certification in Adult and Geriatric Psychiatry.